New and Emerging Agents in the Prevention and Treatment of Venous Thromboembolic Disease
This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Discuss factors that contribute to the risk of VTE and identify high-risk patients who may benefit most from thromboprophylaxis
- Summarize the current standard of care for thromboprophylaxis in patients with cancer
- Review clinical trial data from studies of new and emerging anticoagulation agents
Michael B. Streiff, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 0.75 Participation
- 0.62 Nurse
- 0.75 Pharmacist
- 0.75 Physician